PerkinElmer and Scitara join forces to create tech-driven ‘model of the modern lab’
Both companies will integrate their products to improve data management and automation in a laboratory setting
Analytical technology leader PerkinElmer and cloud-based software provider Scitara have announced a collaboration that combines their product offerings to create a ‘model of the modern lab’.
The move will see PerkinElmer integrate its Signals Research Suite informatics platform with Scitara’s Scientific Integration Platform (SIP) to create a fully connected laboratory with enhanced data management and automation capabilities.
PerkinElmer’s Signals Research Suite provides end-to-end scientific data and workflow management, while Scitara’s SIP provides a universal connectivity solution in a cloud native infrastructure. The deal aligns with PerkinElmer’s strategy of using its informatics offerings to drive digital transformation in the lab.
Scitara’s CEO Ajit Nagral said the agile framework offered by the collaboration guarantees flexibility as standard.
‘It provides the ability to extract maximum value from legacy equipment, while dramatically lowering the barrier to introduce new, innovative technology into the connected lab. We drive data aggregation to any selected customer repository in an agile, compliant and future-proof solution.
A breakthrough level of automation – from the simplest to the most complex tasks – is achieved while complying with the most stringent requirements of regulated markets,' he said.
Earlier this year Scitara raised $15 million in Series B funding, which analysts say was fuelled by the success of its SIP.
Speaking about the collaboration, Kevin Willoe, VP and General Manager, Informatics at PerkinElmer, said merging the two services will create a ‘truly integrated laboratory environment.’
‘This will help tie together instruments, software and systems and support our customers in curating data in a standardized platform. This is the power of the lab of the future in action,’ he said.
Both companies say integrating the SIP infrastructure with the PerkinElmer Signals Research platform will allow for improved data management, enhanced collaboration and more lab automation. Integrated data science can be used in tandem with AI and analytic tools, providing scientists with faster insights, fuelling decision making and ultimately accelerating products to market.
Related News
-
News AI-powered therapy offers hope for rare familial polyposis
Recursion Pharmaceuticals has announced promising results from its ongoing early- to mid-stage trial evaluating its AI-powered treatment, REC-4881, for familial adenomatous polyposis (FAP).
-
News CPHI Podcast Series: AI transforming pharma manufacturing
This episode explores how AI is revolutionising the pharmaceutical industry, from "smart factories" to seamless supply chain integration, and discuss the transformative advancements shaping the next decade.
-
News AstraZeneca invests in AI-led research agreement with China's CSPC, up to US$5.3 billion
Anglo-Swedish pharmaceutical giant AstraZeneca announced they have signed a deal with China’s CSPC Pharmaceutical Group worth up to US$5.3 billion to drive AI-led research development of therapies for chronic conditions.
-
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News How GLP-1 agonists are reshaping drug delivery innovations
GLP-1 agonist drug products like Ozempic, Wegovy, and Mounjaro have taken the healthcare industry by storm in recent years. Originally conceived as treatment for Type 2 diabetes, the weight-loss effects of these products have taken on unprecedented int... -
News 2025 Pharma Trends Outlook: Collaborative Pharma – A New Era of Supply Chains
A new year, a new Pharma Trends Outlook report! The 2025 Pharma Trends Outlook report examines key changes expected in the pharmaceutical industry for the coming year, particularly in regards to the supply chain.
-
News AI-driven drug discovery model sets new accuracy prediction benchmark
Iambic Therapeutics, an Nvidia-backed biotech based in London, have stated that their AI drug discovery model named ‘Enchant’ demonstrates the potential to reduce the time and cost associated with new drug development.
-
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma.